No description available.

[Truncated abstract] Olfactory ensheathing glia (OEG) have been demonstrated to improve functional and anatomical outcomes after injury to the nervous system and are currently being trialled clinically. This thesis presents the investigation of two important issues in OEG biology. The first study (Chapter 2) investigates effects of different members of the neuregulin (NRG) family of molecules on the proliferation of OEG, as a means of quickly obtaining large numbers of cells for clinical or experimental use. We report that NRG-1β, but not NRG- 2α or NRG-3, has a significant proliferative effect. Furthermore, we report for the first time that use of different mitogens (forskolin and pituitary extract) commonly used to expand these cells in vitro, can have a significant effect on the responsiveness of OEG to added NRG in subsequent mitogenic assays. OEG grown initially with forskolin and pituitary extract exhibited increased basal proliferation rates in comparison to OEG originally expanded without these factors, and this increased rate of proliferation was sustained for at least 6 days following their withdrawal from the culture medium. We also report for the first time the expression pattern of ErbB2, ErbB3 and ErbB4 receptors on p75-selected OEG, and investigate their contribution to the NRG mitogenic effect by the use of inhibitory ErbB antibodies. Our second study (Chapter 3) seeks to clarify the role of OEG in promoting myelination of central nervous system neurons. In this study we have investigated the myelinating ability of OEG derived from embryonic (EEG), postnatal (PEG) and adult tissue (AEG) both in vitro and in vivo. OEG selected by p75-immunopanning were co-cultured with dissociated cultures of TrkA-dependant embryonic dorsal root ganglion (DRG) neurons. EEG, but not AEG or PEG, successfully myelinated DRG neurons in the presence of serum and/or ascorbate. AEG also failed to myelinate GDNF-dependant embryonic DRG cultures, and growth factor-independent adult DRG cultures. Transplantation of OEG into lysolecithin demyelinated spinal cord demonstrated distinct ultrastructural differences between transplants of OEG derived from animals of different ages. Furthermore, we demonstrate that clearance of degraded myelin from the lesion site appears to be more effective when animals are transplanted with EEG rather than AEG or Schwann cell preparations. These results suggest that myelinating potential of OEG in vitro and behaviour of these cells following transplantation in vivo are developmentally regulated.

In experimental models of demyelination such as cat optic nerve injected with antibody to galactocerebroside, stepwise and ultimately full repair occurs, starting with recruitment of oligodendrocyte progenitor cells (OP) from surrounding tissue and culminating in remyelination by young competent oligodendrocytes. Endogenous repair of demyelination can also occur in the adult human central nervous system, as evidenced by remyelinated shadow plaques in MS, but ultimately fails in this disease, leading to areas of chronic demyelination where surviving axons are both dysfunctional in terms of conduction and vulnerable to ongoing damage. In order to meaningfully investigate this failure of remyelination in the human situation, an essential prerequisite is to be able to reliably identify the neuroglial cells, and in particular, oligodendrocyte lineage cells, involved in the repair pathway in situ in post mortem tissue. While some marker antigens have been shown to remain demonstrable despite autolytic change and through differing fixation levels, others are far more sensitive and only reliable in freshly obtained tissue with light fixation. For instance, the surface antigens NG2 and PDGFαR, which have been widely used in experimental studies as a marker for OP both in vivo and in vitro, have been shown to be adversely affected by both fixation and autolysis. To this end, the cat optic nerve demyelination model, in which the reparative oligodendrocyte lineage stages have been antigenically defined, was extended to normal optic nerve including lightly fixed tissue. Here, NG2, PDGFαR and the oligodendrocyte lineage transcription factors Olig1 and Olig2 were able to be demonstrated and then correlated with the existing antigenic phenotypes. Subsequently, normal human optic nerve, optimised for both morphological preservation and antigen retention, was used to develop an in vivo staining profile for all neuroglia including OP, that was then applied to conventionally prepared, normal and MS tissue. It was found that, with careful attention to technical parameters such as post mortem interval and details of fixation, OP and other stages of the remyelinating oligodendrocyte lineage could be identified in such material, resulting in meaningful insight into the repair status of the three MS samples studied.

Thesis (Ph. D.)--University of California, San Diego and San Diego State University, 2008. / Title from first page of PDF file (viewed April 7, 2008). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references (p. 127-149).

Thesis (MSc.(Anatomy)--Faculty of Health Sciences)-University of Pretoria, 2007. / Includes bibliographical references.

In this thesis, we aim to investigate the correlation between myelination and the gestational age for preterm infants, with the former being an important developmental process during human brain maturation. Quantification of myelin requires dedicated imaging, but the conventional magnetic resonance images routinely acquired during clinical imaging of neonates carry signatures that are thought to be associated with myelination. This thesis thus focuses on structural segmentation and spatio-temporal modelling of the so-called myelin-like signals on T2-weighted scans for early prognostic evaluation of the preterm brain. The segmentation part poses the major challenges of this task: insufficient spatial prior information of myelination and the presence of substantial partial volume voxels in clinical data. Specific spatial priors for the developing brain are obtained from either probabilistic atlases or manually annotated training images, but none of them currently include myelin as an individual tissue type. This causes further difficulties in partial volume estimation which depends on the probabilistic atlases of the composing pure tissues. Our key contribution is the development of an expectation-maximisation framework that incorporates an explicit partial volume class whose locations are configured in relation to the composing pure tissues in a predefined region of interest via second-order Markov random fields. This approach resolves the above challenges without requiring any probabilistic atlas of myelin. We also investigate atlas-based whole brain segmentation that generates the binary mask for the region of interest. We then construct a spatio-temporal growth model for myelin-like signals using logistic regression based on the automatic segmentations of 114 preterm infants aged between 29 and 44 gestational weeks. Lastly, we demonstrate the ability of age estimation using the normal growth model in a leave-one-out procedure.

Dans cette étude, nous avons utilisé un modèle de souris permettant d’induire des lésions de sévérité variable afin de mimer différentes anomalies de la myéline du cerveau que l'on peut rencontrer chez l'homme. La perte des OLs a été de 80% après 2 semaines de traitement au GCV (GCV1-14). Après l'arrêt du traitement, les processus de récupération ont conduit à une augmentation significative de la population OLs à 80% à la semaine 6 (W6). L’extension du traitement GCV à 3 semaines (GCV1-21) a entraîné une perte de 85% de la population OLs. Cependant la récupération est limitée et reste à 40% du niveau de contrôle à W6. Nous avons remarqué une augmentation rapide (de 2 fois) des cellules Olig2+ chez la souris GCV1-14 contre les souris GCV1-21 (de 1,5 fois) à W4. Nos résultats ont montré une augmentation significative des cellules Olig2-phosphorylé chez la souris GCV1-14 entre W3 et W4 après l'arrêt du traitement GCV. A l'opposé, dans le modèle GCV1-21, un très faible niveau de Olig2 phosphorylé a été observé. Nous avons observé des modifications transitoires dans l’expression de NgR et Caspr mais l’expression de P75 reste inchangée. Ensemble, ces résultats suggèrent que la reprise du déficit myéline du cerveau au cours du développement postnatal dépend de régénération suffisante des oligodendrocytes dans un laps de temps défini pour la myélinisation normale. / Abnormalities of myelination during brain development are thought to result in neurologic and psychiatric disorders. We tested the developmental time window required for oligodendrocyte generation and myelin formation in the central nervous system, using a transgenic mouse harboring HSV1-TK and eGFP genes under the control of MBP and PLP promoters respectively, to carry out the conditional ablation of oligodendrocytes. The first ablation program comprised daily injection of ganciclovir (GCV) for two weeks (GCV1-14) to induce a reversible myelin recovery. The second program comprised GCV injection for 3 weeks (GCV1-21) to create a model of irreversible myelin recovery. GCV1-14 model presented 85% reduction of oligodendrocytes at week 2 (W2) and significantly increased recovery of oligodendrocytes and myelin at W4, then slower recuperation in the following weeks after the arrest of GCV treatment. Similarly, GCV treatment for three weeks (GCV1-21) induced severe deficiency of oligodrndocytes (90%) and myelin at W3. Contrasting the GCV1-14 program, only 40-50% of oligodendrocyte population was recovered at W6 and brain remained severely deficient in myelin. Moreover, no significant recovery was observed during the following weeks and myelin at W4, then slower recuperation in the following weeks after the arrest of GCV treatment. Similarly, GCV treatment for three weeks (GCV1-21) induced severe deficiency of oligodrndocytes (90%) and myelin at W3. Contrasting the GCV1-14 program, only 40-50% of oligodendrocyte population was recovered at W6 and brain remained severely deficient in myelin. Moreover, no significant recovery was observed during the following weeks and frequently ended with premature death of mice. Since no significant changes in the expression of axonal markers including neurofilaments, NgR, P75, Caspr and neurofascin186 were detected at W5 in the two models, we conclude that an intrinsic defect of oligodendrocyte regeneration at W3-W4 underlies the irreversible model. Significant number of phosphorylated Olig2+ cells was observed at W3 in reversible model in demyelinated corpus callosum while at the same time-point, this population is absent from control and irreversible model. At the same period, the proliferation index (Ki67) of Olig2+ cells is 8 fold higher in the corpus callosum of GCV1-14 model than the control and the irreversible model. Together, these findings suggest that recovery from myelin deficit during postnatal brain development depends on sufficient regeneration of oligodendrocytes within a defined time frame for normal myelination to occur.

Schwann cells are the principal glial cell of the peripheral nervous system and are responsible for axon maintenance, regeneration and increasing saltatory conduction of neurons. Schwann cell differentiation and myelination is mediated by a core network of transcription factors and signalling pathways, which have been divided into two groups; positive and negative regulators. Sox10, NFATc4, Oct6, Krox20 and the ERK 1/2 signalling pathway have been characterised as positive regulators of Schwann cell differentiation and myelination; with Sox10 and Krox20 also playing critical roles in myelin maintenance. On the other hand, transcription factors cJun, Pax3, Id2 and signalling pathways Notch and p38 mitogen activated protein (MAP) kinases (MAPK) have been identified as negative regulators of Schwann cell differentiation and myelin formation. Recently, the HMG transcription factor Sox2 was identified as a negative regulator of Schwann cell myelination in vitro, however its role in Schwann cell myelination in vivo has not yet been studied. This study therefore aimed to examine the role of Sox2 overexpression in Schwann cells and how it effects Schwann cell differentiation and myelination during development and after injury. In addition, we aimed to investigate for the first time the specific role of p38α (the major isoform of p38 MAPK) in Schwann cell myelination in vivo, by generating Schwann cell specific p38α conditional knockout mice. Sox2 is highly expressed in immature Schwann cells, but is downregulated as Schwann cells being to mature and differentiate. This study shows that continued expression of Sox2 during development and after injury, impairs Schwann cell differentiation and myelination by directly downregulating the expression of two core transcription factors; Sox10 and Krox20, as well as myelin proteins, P0 and MBP. In addition, we observe that continued Sox2 expression significantly increases Schwann cell proliferation and maintains Schwann cells in an immature state. Unexpectedly, we also observed that continued Sox2 expression significantly increases the number of macrophages present in the nerves of Sox2 overexpressing mice at both P60 and 21 days post injury. Phenotypically, Sox2 overexpressing mice 6 show signs of a peripheral neuropathy and animals have impaired motor and sensory function. These findings confirm that Sox2 is a negative regulator of Schwann cell myelination and suggests that continued Sox2 expression is sufficient to drive the progressive development of a peripheral nerve disorder which may resemble Charcot-Marie-Tooth type 1 demyelinating neuropathy and congenital hypomyelinating neuropathy. As a negative regulator of Schwann cell myelination, activity of the p38 MAPK pathway has been shown to inhibit myelin formation in vitro and to also induce the Schwann cell injury response; by driving Schwann cell dedifferentiation and demyelination following injury. Here we show that specific removal of the p38α isoform in Schwann cells leads to an increase in myelin thickness at early developmental time-points, along with an elevated expression of myelin proteins, P0 and MBP. Further analysis following nerve injury revealed that removal of p38α results in an initial decrease in Schwann cell demyelination, yet improves axon remyelination at 21 days post injury. These results demonstrate the specific role of p38α in regulating Schwann cell myelination, and how it could be a direct therapeutic target for improving nerve repair after injury.

SOX17 est un facteur de transcription à motif HMG-box, du sous-groupe SoxF, identifié comme étant un nouveau régulateur du développement oligodendrocytaire. L’expression de SOX17 est maximale au stade oligodendrocyte pré-myélinisant. In vitro, les approches de gain et perte de fonction de Sox17 suggèrent que ce facteur favorise la sortie de cycle et/ou la différenciation des OPCs (Sohn et al., 2006). In vivo, la fonction de SOX17 dans la prolifération et la différenciation des OPCs, restait à déterminer. Afin d’établir le rôle de SOX17 in vivo, nous avons généré un modèle de souris transgénique de surexpression inductible sous le contrôle du promoteur Sox10 (système Tet-On). Après traitement à la doxycycline, la surexpression de Sox17 est effective dans les cellules oligodendrogliales du système nerveux central (SNC) et les dérivés des crêtes neurales du système nerveux périphérique (SNP). Les souris TetSox17;Sox10rtTA/+ présentent un phénotype moteur sévère. Nos données montrent que la surexpression de Sox17 induit un délai de la différenciation des OPCs causant une hypomyélinisation de la moelle épinière. L’analyse de la myélinisation chez les souris KO conditionnel, Cnpase-cre;Sox17flox/flox, révèle que Sox17 n’est pas nécessaire à la myélinisation du SNC. De plus, au sein du SNP, le gain de fonction Sox17 provoque un défaut du processus de radial sorting et un blocage des cellules de Schwann au stade pro-myélinisant, résultant en une inhibition de la myélinisation. Nos résultats indiquent une fonction stade-dépendant de Sox17 sur la progression du lignage oligodendrocytaire et identifie Sox17 comme un nouveau régulateur du développement de la cellule de Schwann. / In the central nervous system (CNS), myelination is timely regulated by oligodendroglial cell lineage progression. During development, the transition from proliferative/migrating oligodendrocyte precursor cells (OPCs) towards myelinating oligodendrocytes occurs through OPC cycle exit and differentiation. The HMG-box transcription factor Sox17 was previously identified as a new regulator of oligodendrocyte development. The expression of Sox17 peaks at the pre-myelinating stage. In vitro gain- and loss-of-function experiments showed that Sox17 promotes OPC cycle exit and differentiation (Sohn et al., 2006). However in vivo, the function of Sox17 in oligodendrocyte development has not been reported. In the present, we generated a transgenic mouse model overexpressing Sox17 in Sox10+ cells, in a doxycycline (DOX)-inducible manner (Tet-ON system). After DOX treatment, gain of Sox17 function was effective in oligodendroglial cells and neural crest derivatives. Interestingly, Sox17-overexpressing mice exhibited severe motor deficits. Our results demonstrated that SOX17 overexpression induces a delay of OPC differentiation, leading to a severe hypomyelination in the developing spinal cord. Furthermore, our analysis of Cnpase-cre;Sox17flox/flox conditional null mice showed that Sox17 is not required for CNS myelination. Remarkably, our data revealed that Sox17 overexpression inhibits PNS myelination, due to defects of radial sorting and inhibition of Schwann cell at the pro-myelinating stage. Altogether, our data provide new insights into stage-specific functions of Sox17 in oligodendroglial cells and identify Sox17 as a potential regulator of Schwann cell development.

No description available.